Vertex neutral rating unchanged by Merrill

Vertex Pharmaceuticals Inc. was kept at a neutral rating by Merrill Lynch analyst Hari Sambasivam following the company's outlook after an earnings call. Merrill is forecasting for the first quarter total revenues of $39.5 million, compared with $28.6 million for the same quarter last year. The analyst will review the rating once there is clarity on the clinical development strategy for VX-950. Shares of the Cambridge, Mass., pharmaceutical company were down 9 cents, or 0.23%, at $39.17 on volume of 1,515,484 shares versus the three-month running average of 1,755,990 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.